Vaxart (OTCMKTS:VXRT) Share Price Crosses Below 200 Day Moving Average – What’s Next?

Shares of Vaxart, Inc. (OTCMKTS:VXRT) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.62 and traded as low as $0.5301. Vaxart shares last traded at $0.5473, with a volume of 297,131 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research raised Vaxart to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Vaxart currently has an average rating of “Hold”.

Vaxart Trading Down 0.2%

The firm has a market cap of $132.59 million, a price-to-earnings ratio of 3.64 and a beta of 1.09. The stock’s 50 day moving average is $0.61 and its 200 day moving average is $0.62.

Vaxart (OTCMKTS:VXRT) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $39.23 million during the quarter, compared to the consensus estimate of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%. On average, equities research analysts predict that Vaxart, Inc. will post -0.68 EPS for the current year.

Institutional Investors Weigh In On Vaxart

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in Vaxart in the 1st quarter worth about $31,000. Creative Planning acquired a new stake in shares of Vaxart during the second quarter valued at about $33,000. Invesco Ltd. boosted its stake in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares in the last quarter. Raymond James Financial Inc. boosted its stake in shares of Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the last quarter. 18.05% of the stock is owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.